Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Goodwill (2020 - 2026)

Cytek Biosciences filings provide 6 years of Goodwill readings, the most recent being $16.7 million for Q4 2025.

  • On a quarterly basis, Goodwill changed 0.2% to $16.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.7 million, a 0.2% change, with the full-year FY2025 number at $16.7 million, changed 0.2% from a year prior.
  • Goodwill hit $16.7 million in Q4 2025 for Cytek Biosciences, roughly flat from $16.7 million in the prior quarter.
  • In the past five years, Goodwill ranged from a high of $19.1 million in Q1 2023 to a low of $476000.0 in Q2 2021.
  • Median Goodwill over the past 5 years was $16.2 million (2023), compared with a mean of $13.4 million.
  • Biggest five-year swings in Goodwill: skyrocketed 2031.09% in 2021 and later dropped 15.46% in 2024.
  • Cytek Biosciences' Goodwill stood at $10.1 million in 2021, then changed by 0.0% to $10.1 million in 2022, then skyrocketed by 59.53% to $16.2 million in 2023, then rose by 2.97% to $16.7 million in 2024, then rose by 0.2% to $16.7 million in 2025.
  • The last three reported values for Goodwill were $16.7 million (Q4 2025), $16.7 million (Q3 2025), and $16.7 million (Q2 2025) per Business Quant data.